AAVogen

Cancer cachexia, muscular dystrophies, sarcopenia & other indications

Designed for superior effectiveness, enhanced specificity and safety


AVGN7 is a viral gene therapeutic that blocks the inhibitory actions of myostatin, GDF11 and activin. In animal studies, its specificity for muscle and heart prevents their wasting without the dangerous side effects that have limited competing technologies.

Novel, targeted gene therapeutics to combat muscle wasting disease.

AAVogen leadership has over 115 years of combined experience in biotech management and muscle disease research. They are advised by internationally recognized athorities and are partnering  with established research organizations.

Gene therapy to strengthen muscle, to fight disease.

AAVogen's mission is to make you stronger.  The company was founded by a family directly impacted by two muscle wasting diseases, Duchenne muscular dystrophy and cancer cachexia.  It is committed not only to patients and their families, but to fellow scientists, companies and investors who share our vision.


Preclinical studies indicate that AVGN7 prevents muscle wasting in animals with cancer and can restore muscle mass and strength even after wasting has already occurred.  It works by blocking biochemical pathways commonly activated in different disease states.  Thus, its potential use as a therapeutic provides hope to many patients and families who understand the difficulties of coping, fighting and surviving a muscle wasting disease.

The AAVogen team, business model, partners

AVGN7

(rAAV:Smad7)
Muscle wasting occurs in patients with cancer, muscular dystrophy, COPD, chronic kidney disease, nerve damage or heart failure. It also occurs with aging and in each situation, can have fatal consequences.